



REPUBLIC OF THE PHILIPPINES
DEPARTMENT OF JUSTICE
OFFICE OF THE GOVERNMENT CORPORATE COUNSEL
3rd Floor MWSS Administration Building, Katipunan Road
Bahara, Quezon City

ANNEX "K"

RECEIVED
LEGASPI VILLAGE
LAW OFFICES
17 February 2006
5:10
Melen

February 7, 2006

ESGUERRA AND BLANCO LAW OFFICES

4/F S & L Building
Dela Rosa cor. Esteban Sts.
Legaspi Village, Makati City

Attn.: Attys. Ramon S. Esguerra
Carlos Paulo M. Villaruz

Gentlemen:

Our client, Philippine International Trading Corporation (PITC), has referred to us your demand letter dated January 17, 2006 (duly received by PITC last January 20, 2006) relative to "amlodipine besylate" which your client, Pfizer, Limited and Pfizer, Inc. distributes in the Philippines as "Norvasc".

In this regard, please be informed that PITC is not unmindful of the rights conferred by law on the holder of a valid patent. The issuance by the BFAD, however, of the Certificate of Product Registration (CPR) over the said product, in PITC's name, does not per se amount to making, using, offering for sale, selling or importing that product which will thereby constitute infringement of patent rights or a violation of Section 71 of Republic Act 8293 (Intellectual Property Code).

In this connection, your apprehension that the grant of the Certificate of Product Registration (CPR) over amlodipine besylate will lead to a violation of patent rights, please be assured that, since the issuance of the CPR, PITC has not imported nor distributed Norvasc in the Philippines and firmly intends to respect the subsisting patent rights of Pfizer Limited and Pfizer, Inc. Thus, there is no basis for your client Pfizer to require PITC to execute an undertaking to surrender the CPR issued by BFAD in its name.

We hope this will sufficiently clarify the position of PITC on the matter.

Very truly yours,


AGNES VST DEVANADERA
Government Corporate Counsel